EFG International’s ImmunityBio IBRX Stock Holding History

EFG International’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$11.8K	Hold	1,350	–	–	﹤0.01%	959
2026 Q1	$10.4K	Hold	1,350	–	–	﹤0.01%	915
2025 Q4	$2.67K	Buy	+1,350	New	+$3.06K	﹤0.01%	844

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

EFG International's IBRX Position: Q2 2026 in Review

EFG International held its ImmunityBio (IBRX) position steady in Q2 2026 at 1,350 shares worth $11.8K. The position accounts for ﹤0.01% of the portfolio, ranked #959.

EFG International first reported a position in IBRX in Q4 2025 and has held it in 3 quarters since. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

EFG International held 1,350 shares of ImmunityBio worth $11.8K as of Q2 2026.
EFG International left its ImmunityBio share count unchanged in Q2 2026.
ImmunityBio made up ﹤0.01% of EFG International's portfolio in Q2 2026, its #959 holding.
EFG International first reported a position in ImmunityBio in Q4 2025 and has held it in 3 quarters since.
405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on EFG International's 13F filing for Q2 2026, filed 14 Aug 2026.